George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I am expecting good news on progress on expect USA distribution. That is where the money is and lots of it. Should give us all a lift and we should get a hardening of the share price.
I've registered for the prenstation so let see what they say....fingers crossed........
Indeed, well done kdonkey let's see what occurs come Wednesday.
Was worth a shot, thanks for trying!
Got a pretty useless response to the list of things I wanted to hear from FUM in the resulsts on Wednesday. - so will be interesting to see if they actually answer any of them during the presentation
--------------------------------------------------------------------------------------------------------------------------------------------------------------
Good afternoon,
Many thanks for getting in touch. On Wednesday at 9am, there is a presentation via the Investor Meet Company platform, for investors in and followers of Futura Medical plc, during which an update on strategic progress will be included alongside the opportunity for Q&A.
Please see the link to register for the presentation here: https://www.investormeetcompany.com/futura-medical-plc/register-investor.
Kind regards,
Spot on there, rpg7. Toli changes with the wind, he could be talking about himself here - 'Watch them ramp it up as it goes down and vise verse its facinating'
Solid buying
Not at all I am a great fan BUT AT THE RIGHT PRICE not too how
A bit ironic coming from you toli.
Desperate to knock price before results desperate
Watch them ramp it up as it goes down and vise verse its facinating
The de rampers trying desperately to lower price before results
Out out.
Or just out?
RNS states investor presentation as well as financial results! This is not the normal year on year results only! and can only assume that the BOD recognises that private investors are entitled to more information with a mention of answering investors submitted questions! I’m in hope of a positive outcome on the 10th otherwise I’m out!
The fact that we cannot get the SP back over 40 suggests to me that expectations for these results are especially low now- we have not rolled out to all the countries we thought by the deadline we set (from what I can see on the website), nothing on USA side, poor |Amazon reviews, no follow through from NHS prescriptions side and how they plan to ramp this up, TV advertising budgets cooling off, little visibility on repeat customers etc etc
I am an optimist, but many I suspect will look for a lot more reassurance than simply reposting last year's numbers that are broadly known and a few optimistic nice hopes for the year ahead - in my worst case scenario that is what we may get and a slide back to 35p etc etc - just my thoughts but until we get SP above 45-50 there remains much doubt in this business model to be proven - I hope the management are on top of all this ! dyor etc
You can read this both ways - a delaying/blocking strategy or a way to better understand the value of eroxon as part of much closer involvement - would they want an equity involvement at any point too. We simple do not know, but we are reaching the point of telling the firm to get going or to get lost. The drawback of the latter is that we are very dependent on their cashflow for 2024 - so this limits us being too aggressive I suspect.
I don’t think the BOD will have left themselves open to Haleon delays, they terminated the china deal because they hadn’t met deadlines, so same will apply with Haleon! Milestones must be being met, and as pointed out they have been caught out before so doubt they will let it happen again!
Pfizer owns Viagra. Pfizer still owns circa 22% of Haleon. Is there a defined pathway/bulletproof agreement for Haleon to launch Eroxon in the US. Question for the BOD
FUM have already declared they are achieving 20% market share, if this has been maintained since last update then surely this is a better indication of repeat sales? I would like % of ED market taken in other territories if we are looking at 20% across the board then happy days! you do the maths.
Not directly relevant but just saw an interesting article listing the top ten shares held by AJ Bell ISA millionaires. Haleon is one of those top ten. Perhaps fffers some reassurance that, if Haleon are involved with Eroxon, they know what they are doing, and we should be on to a winner.
It's not the initial sales of eroxon I'm wondering about , it's purely the repeat orders coming in that really matters , and yes it maybe far to early to expect to much information around repeat orders coming in to futura. If eroxon gets good repeat orders from even a continuation of good shop sales then futura's shares will fly here, I only have the trials data to go on and that's excellent ok, though continuous physical shop sales are needed to confirm a good solid traction into this market place, boots surely would have those continuous sales figures for every month from launch day, also James Barder could easily attain those figures from boots etc, or even the eroxon manufacturers , on the 10th April surly someone will ask James barder the obvious question then ?. I'm sure it's doing ok, but is Eroxon still selling well compared to viagra. this product could still be a worldwide blockbuster, though the size of upfront milestone payments from other countries will tell us how Eroxon is selling in the UK and Europe.
Gla
Acer,
If punters give the management a “ real challenge” over a firm date for the launch in the U.S. then they won’t know ( or want to know ) that FUTURA are not responsible for the product distribution or advertising.
That is solely down to HALEON so any announcement on APRIL 10 on a U.S. launch date will be most unlikely unless it’s made by HALEON .
However we should get a reasonably accurate indicate as to sales of EROXON over the first 4 to six months of trading in Belgium and U.K up to the end of
2023 all made via Coopers.
GLA . Arturo.
I think much of the amazon business is down to the fact that this was pretty much the only place you could buy the product - it has taken to last month for my local boots to get some eroxon in. My hope is that all the different sources of sales outlets will mean that customers can buy via a local store or via a preferred outlet e.g. superdrug to name but one.
I am hopeful for the future but very realistic on the current sales as we have only just got full coverage in UK, only started in all the overseas areas and nothing in the US. The negative reviews on Amazon (many fake I suggest) have clearly going to have an effect so it all needs to settle down.
We need to find the niche of customers who have sensitivity down below to find an effect from the gel, are unable to use the blue pills for whatever reason (or will choose not to use them), have partners who do not object to the gel entering them etc etc. There are so many decision points on this gel and I think it will take another 12 months to let the dust settle.
Having said all of that, if we do not get a firm date for USA launch, then I think our management will be in for a real challenge from the shareholders - in terms of managing time expectations for roll outs.
GT. Amazon tells you when you search for a product and hover over. It’s one of their version of social proofing as a sales tactic.
Coordinated marketing launch is what is required.
OTC sales will not be insignificant however, online sales is where it's at. I would not be surprised if Eroxon project managers from the distribution companies are not meeting regularly. Successful launch of Eroxon is in everyone concerned's interest.
Whether any news of this is tied in with the results , we'll have to see. Results on their own will not cut the mustard. IMO
UK Customers can now get Eroxon on NHS prescription, so OTC sales may appear to drop but this isn’t likely to be the case. Coopers and Haleon will be able to analyse demand through NHS contracts, which is highly significant in my view.